nodes	percent_of_prediction	percent_of_DWPC	metapath
Buprenorphine—CYP2C18—prostate cancer	0.117	0.33	CbGaD
Buprenorphine—CYP3A5—prostate cancer	0.0768	0.217	CbGaD
Buprenorphine—CYP2A6—prostate cancer	0.0744	0.21	CbGaD
Buprenorphine—CYP2C19—prostate cancer	0.0523	0.148	CbGaD
Buprenorphine—CYP3A4—prostate cancer	0.0332	0.0941	CbGaD
Buprenorphine—ABCG2—Cabazitaxel—prostate cancer	0.0162	0.0401	CbGbCtD
Buprenorphine—ABCG2—Estrone—prostate cancer	0.0158	0.0392	CbGbCtD
Buprenorphine—CYP2C8—Nilutamide—prostate cancer	0.0141	0.0349	CbGbCtD
Buprenorphine—CYP3A5—Flutamide—prostate cancer	0.0121	0.03	CbGbCtD
Buprenorphine—CYP2C19—Nilutamide—prostate cancer	0.0118	0.0292	CbGbCtD
Buprenorphine—CYP2C19—Bicalutamide—prostate cancer	0.0118	0.0292	CbGbCtD
Buprenorphine—CYP2C8—Abiraterone—prostate cancer	0.0117	0.0289	CbGbCtD
Buprenorphine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0109	0.0269	CbGbCtD
Buprenorphine—ABCG2—Conjugated Estrogens—prostate cancer	0.0103	0.0256	CbGbCtD
Buprenorphine—CYP2C9—Bicalutamide—prostate cancer	0.00981	0.0243	CbGbCtD
Buprenorphine—CYP2C9—Nilutamide—prostate cancer	0.00981	0.0243	CbGbCtD
Buprenorphine—CYP2C19—Flutamide—prostate cancer	0.00978	0.0242	CbGbCtD
Buprenorphine—ABCG2—Mitoxantrone—prostate cancer	0.00941	0.0233	CbGbCtD
Buprenorphine—ABCG2—Estradiol—prostate cancer	0.00908	0.0225	CbGbCtD
Buprenorphine—CYP1A2—Flutamide—prostate cancer	0.00902	0.0224	CbGbCtD
Buprenorphine—CYP2D6—Bicalutamide—prostate cancer	0.00897	0.0222	CbGbCtD
Buprenorphine—CYP3A5—Cabazitaxel—prostate cancer	0.00897	0.0222	CbGbCtD
Buprenorphine—ABCB1—Estramustine—prostate cancer	0.00885	0.0219	CbGbCtD
Buprenorphine—CYP3A5—Estrone—prostate cancer	0.00876	0.0217	CbGbCtD
Buprenorphine—CYP2C8—Cabazitaxel—prostate cancer	0.00862	0.0214	CbGbCtD
Buprenorphine—CYP2C8—Ethinyl Estradiol—prostate cancer	0.00751	0.0186	CbGbCtD
Buprenorphine—CYP2D6—Abiraterone—prostate cancer	0.00743	0.0184	CbGbCtD
Buprenorphine—CYP3A7—Estradiol—prostate cancer	0.00671	0.0166	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Estradiol—prostate cancer	0.00671	0.0166	CbGbCtD
Buprenorphine—CYP1A2—Estrone—prostate cancer	0.00652	0.0162	CbGbCtD
Buprenorphine—ABCG2—Etoposide—prostate cancer	0.00593	0.0147	CbGbCtD
Buprenorphine—CYP2C9—Estrone—prostate cancer	0.00588	0.0146	CbGbCtD
Buprenorphine—ABCB1—Cabazitaxel—prostate cancer	0.00584	0.0145	CbGbCtD
Buprenorphine—CYP3A4—Bicalutamide—prostate cancer	0.0057	0.0141	CbGbCtD
Buprenorphine—ABCB1—Estrone—prostate cancer	0.0057	0.0141	CbGbCtD
Buprenorphine—ABCG2—Docetaxel—prostate cancer	0.00543	0.0134	CbGbCtD
Buprenorphine—CYP3A4—Estramustine—prostate cancer	0.0053	0.0131	CbGbCtD
Buprenorphine—ABCB1—Ethinyl Estradiol—prostate cancer	0.00508	0.0126	CbGbCtD
Buprenorphine—CYP3A5—Estradiol—prostate cancer	0.00503	0.0125	CbGbCtD
Buprenorphine—CYP2C8—Estradiol—prostate cancer	0.00484	0.012	CbGbCtD
Buprenorphine—CYP3A4—Flutamide—prostate cancer	0.00473	0.0117	CbGbCtD
Buprenorphine—CYP3A4—Abiraterone—prostate cancer	0.00473	0.0117	CbGbCtD
Buprenorphine—CYP2C9—Capecitabine—prostate cancer	0.00445	0.011	CbGbCtD
Buprenorphine—CYP1A2—Conjugated Estrogens—prostate cancer	0.00427	0.0106	CbGbCtD
Buprenorphine—CYP2C19—Estradiol—prostate cancer	0.00406	0.0101	CbGbCtD
Buprenorphine—ABCG2—Doxorubicin—prostate cancer	0.00405	0.01	CbGbCtD
Buprenorphine—CYP3A7-CYP3A51P—Docetaxel—prostate cancer	0.00401	0.00993	CbGbCtD
Buprenorphine—CYP3A7—Docetaxel—prostate cancer	0.00401	0.00993	CbGbCtD
Buprenorphine—CYP1A2—Estradiol—prostate cancer	0.00375	0.00928	CbGbCtD
Buprenorphine—ABCB1—Conjugated Estrogens—prostate cancer	0.00373	0.00925	CbGbCtD
Buprenorphine—CYP3A4—Cabazitaxel—prostate cancer	0.0035	0.00866	CbGbCtD
Buprenorphine—CYP2C19—Prednisone—prostate cancer	0.00349	0.00865	CbGbCtD
Buprenorphine—CYP3A4—Estrone—prostate cancer	0.00342	0.00847	CbGbCtD
Buprenorphine—ABCB1—Mitoxantrone—prostate cancer	0.00339	0.0084	CbGbCtD
Buprenorphine—CYP2C9—Estradiol—prostate cancer	0.00338	0.00836	CbGbCtD
Buprenorphine—CYP3A5—Etoposide—prostate cancer	0.00329	0.00814	CbGbCtD
Buprenorphine—ABCB1—Estradiol—prostate cancer	0.00328	0.00812	CbGbCtD
Buprenorphine—CYP2C8—Etoposide—prostate cancer	0.00316	0.00783	CbGbCtD
Buprenorphine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00305	0.00755	CbGbCtD
Buprenorphine—CYP3A5—Docetaxel—prostate cancer	0.00301	0.00745	CbGbCtD
Buprenorphine—ABCB1—Prednisone—prostate cancer	0.00282	0.00698	CbGbCtD
Buprenorphine—CYP1A2—Etoposide—prostate cancer	0.00245	0.00606	CbGbCtD
Buprenorphine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00224	0.00554	CbGbCtD
Buprenorphine—ABCB1—Etoposide—prostate cancer	0.00214	0.0053	CbGbCtD
Buprenorphine—CYP3A4—Mitoxantrone—prostate cancer	0.00203	0.00504	CbGbCtD
Buprenorphine—CYP3A4—Estradiol—prostate cancer	0.00196	0.00486	CbGbCtD
Buprenorphine—ABCB1—Docetaxel—prostate cancer	0.00196	0.00485	CbGbCtD
Buprenorphine—CYP3A4—Prednisone—prostate cancer	0.00169	0.00418	CbGbCtD
Buprenorphine—ABCB1—Doxorubicin—prostate cancer	0.00146	0.00361	CbGbCtD
Buprenorphine—CYP2D6—Doxorubicin—prostate cancer	0.00137	0.00341	CbGbCtD
Buprenorphine—CYP2C19—urine—prostate cancer	0.00132	0.0877	CbGeAlD
Buprenorphine—CYP3A4—Etoposide—prostate cancer	0.00128	0.00318	CbGbCtD
Buprenorphine—CYP3A4—Docetaxel—prostate cancer	0.00117	0.00291	CbGbCtD
Buprenorphine—CYP1A2—urine—prostate cancer	0.00108	0.0716	CbGeAlD
Buprenorphine—CYP2C9—urine—prostate cancer	0.00103	0.068	CbGeAlD
Buprenorphine—OPRK1—prostate gland—prostate cancer	0.00097	0.0642	CbGeAlD
Buprenorphine—CYP3A4—Doxorubicin—prostate cancer	0.000874	0.00217	CbGbCtD
Buprenorphine—UGT1A9—renal system—prostate cancer	0.000872	0.0577	CbGeAlD
Buprenorphine—OPRL1—testis—prostate cancer	0.000865	0.0573	CbGeAlD
Buprenorphine—CYP3A4—urine—prostate cancer	0.000783	0.0518	CbGeAlD
Buprenorphine—Naloxone—TLR4—prostate cancer	0.000778	0.617	CrCbGaD
Buprenorphine—CYP2D6—urine—prostate cancer	0.00077	0.051	CbGeAlD
Buprenorphine—CYP2A6—prostate gland—prostate cancer	0.000739	0.0489	CbGeAlD
Buprenorphine—OPRD1—renal system—prostate cancer	0.000689	0.0456	CbGeAlD
Buprenorphine—OPRL1—lymph node—prostate cancer	0.000627	0.0415	CbGeAlD
Buprenorphine—CYP2A6—seminal vesicle—prostate cancer	0.000625	0.0414	CbGeAlD
Buprenorphine—ABCG2—prostate gland—prostate cancer	0.000403	0.0267	CbGeAlD
Buprenorphine—CYP3A5—prostate gland—prostate cancer	0.000374	0.0248	CbGeAlD
Buprenorphine—ABCG2—seminal vesicle—prostate cancer	0.000341	0.0226	CbGeAlD
Buprenorphine—OPRM1—testis—prostate cancer	0.000304	0.0201	CbGeAlD
Buprenorphine—CYP2C8—renal system—prostate cancer	0.000283	0.0187	CbGeAlD
Buprenorphine—ABCG2—urethra—prostate cancer	0.00027	0.0179	CbGeAlD
Buprenorphine—CYP1A2—renal system—prostate cancer	0.000265	0.0175	CbGeAlD
Buprenorphine—CYP3A5—renal system—prostate cancer	0.000255	0.0169	CbGeAlD
Buprenorphine—Naloxone—ESR1—prostate cancer	0.000218	0.173	CrCbGaD
Buprenorphine—ABCG2—bone marrow—prostate cancer	0.000208	0.0138	CbGeAlD
Buprenorphine—ABCB1—prostate gland—prostate cancer	0.000199	0.0132	CbGeAlD
Buprenorphine—CYP3A4—renal system—prostate cancer	0.000192	0.0127	CbGeAlD
Buprenorphine—CYP2D6—renal system—prostate cancer	0.000188	0.0125	CbGeAlD
Buprenorphine—CYP2C8—testis—prostate cancer	0.000183	0.0121	CbGeAlD
Buprenorphine—ABCG2—testis—prostate cancer	0.000178	0.0118	CbGeAlD
Buprenorphine—ABCB1—seminal vesicle—prostate cancer	0.000168	0.0111	CbGeAlD
Buprenorphine—Oxymorphone—CYP3A4—prostate cancer	0.000153	0.121	CrCbGaD
Buprenorphine—ABCB1—epithelium—prostate cancer	0.000146	0.00968	CbGeAlD
Buprenorphine—ABCB1—renal system—prostate cancer	0.000136	0.00898	CbGeAlD
Buprenorphine—ABCB1—urethra—prostate cancer	0.000133	0.00882	CbGeAlD
Buprenorphine—ABCG2—lymph node—prostate cancer	0.000129	0.00853	CbGeAlD
Buprenorphine—CYP2D6—testis—prostate cancer	0.000122	0.00807	CbGeAlD
Buprenorphine—Naloxone—CYP3A4—prostate cancer	0.000111	0.0884	CrCbGaD
Buprenorphine—ABCB1—bone marrow—prostate cancer	0.000103	0.00679	CbGeAlD
Buprenorphine—ABCB1—testis—prostate cancer	8.76e-05	0.0058	CbGeAlD
Buprenorphine—ABCB1—lymph node—prostate cancer	6.35e-05	0.00421	CbGeAlD
Buprenorphine—Hypotension—Capecitabine—prostate cancer	2.65e-05	0.000205	CcSEcCtD
Buprenorphine—Insomnia—Docetaxel—prostate cancer	2.65e-05	0.000205	CcSEcCtD
Buprenorphine—Myalgia—Prednisone—prostate cancer	2.63e-05	0.000204	CcSEcCtD
Buprenorphine—Arthralgia—Prednisone—prostate cancer	2.63e-05	0.000204	CcSEcCtD
Buprenorphine—Paraesthesia—Docetaxel—prostate cancer	2.63e-05	0.000204	CcSEcCtD
Buprenorphine—Anxiety—Prednisone—prostate cancer	2.63e-05	0.000204	CcSEcCtD
Buprenorphine—Bradycardia—Doxorubicin—prostate cancer	2.62e-05	0.000203	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	2.62e-05	0.000203	CcSEcCtD
Buprenorphine—Dyspnoea—Docetaxel—prostate cancer	2.61e-05	0.000202	CcSEcCtD
Buprenorphine—Somnolence—Docetaxel—prostate cancer	2.6e-05	0.000202	CcSEcCtD
Buprenorphine—Discomfort—Prednisone—prostate cancer	2.6e-05	0.000202	CcSEcCtD
Buprenorphine—Eye disorder—Epirubicin—prostate cancer	2.6e-05	0.000201	CcSEcCtD
Buprenorphine—Hypersensitivity—Etoposide—prostate cancer	2.6e-05	0.000201	CcSEcCtD
Buprenorphine—Tinnitus—Epirubicin—prostate cancer	2.59e-05	0.000201	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Capecitabine—prostate cancer	2.58e-05	0.0002	CcSEcCtD
Buprenorphine—Flushing—Epirubicin—prostate cancer	2.58e-05	0.0002	CcSEcCtD
Buprenorphine—Cardiac disorder—Epirubicin—prostate cancer	2.58e-05	0.0002	CcSEcCtD
Buprenorphine—Rhinitis—Doxorubicin—prostate cancer	2.58e-05	0.0002	CcSEcCtD
Buprenorphine—Dyspepsia—Docetaxel—prostate cancer	2.58e-05	0.0002	CcSEcCtD
Buprenorphine—Insomnia—Capecitabine—prostate cancer	2.56e-05	0.000199	CcSEcCtD
Buprenorphine—Hypoaesthesia—Doxorubicin—prostate cancer	2.56e-05	0.000198	CcSEcCtD
Buprenorphine—Pharyngitis—Doxorubicin—prostate cancer	2.55e-05	0.000198	CcSEcCtD
Buprenorphine—Paraesthesia—Capecitabine—prostate cancer	2.55e-05	0.000197	CcSEcCtD
Buprenorphine—Decreased appetite—Docetaxel—prostate cancer	2.55e-05	0.000197	CcSEcCtD
Buprenorphine—Urinary tract disorder—Doxorubicin—prostate cancer	2.54e-05	0.000197	CcSEcCtD
Buprenorphine—Oedema peripheral—Doxorubicin—prostate cancer	2.53e-05	0.000196	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Docetaxel—prostate cancer	2.53e-05	0.000196	CcSEcCtD
Buprenorphine—Asthenia—Etoposide—prostate cancer	2.53e-05	0.000196	CcSEcCtD
Buprenorphine—Connective tissue disorder—Doxorubicin—prostate cancer	2.53e-05	0.000196	CcSEcCtD
Buprenorphine—Dyspnoea—Capecitabine—prostate cancer	2.53e-05	0.000196	CcSEcCtD
Buprenorphine—Oedema—Prednisone—prostate cancer	2.53e-05	0.000196	CcSEcCtD
Buprenorphine—Anaphylactic shock—Prednisone—prostate cancer	2.53e-05	0.000196	CcSEcCtD
Buprenorphine—Fatigue—Docetaxel—prostate cancer	2.53e-05	0.000196	CcSEcCtD
Buprenorphine—Angiopathy—Epirubicin—prostate cancer	2.52e-05	0.000196	CcSEcCtD
Buprenorphine—Urethral disorder—Doxorubicin—prostate cancer	2.52e-05	0.000195	CcSEcCtD
Buprenorphine—Nausea—Mitoxantrone—prostate cancer	2.52e-05	0.000195	CcSEcCtD
Buprenorphine—Immune system disorder—Epirubicin—prostate cancer	2.51e-05	0.000195	CcSEcCtD
Buprenorphine—Infection—Prednisone—prostate cancer	2.51e-05	0.000195	CcSEcCtD
Buprenorphine—Mediastinal disorder—Epirubicin—prostate cancer	2.51e-05	0.000194	CcSEcCtD
Buprenorphine—Constipation—Docetaxel—prostate cancer	2.5e-05	0.000194	CcSEcCtD
Buprenorphine—Pain—Docetaxel—prostate cancer	2.5e-05	0.000194	CcSEcCtD
Buprenorphine—Dyspepsia—Capecitabine—prostate cancer	2.5e-05	0.000193	CcSEcCtD
Buprenorphine—Chills—Epirubicin—prostate cancer	2.49e-05	0.000193	CcSEcCtD
Buprenorphine—Pruritus—Etoposide—prostate cancer	2.49e-05	0.000193	CcSEcCtD
Buprenorphine—Shock—Prednisone—prostate cancer	2.49e-05	0.000193	CcSEcCtD
Buprenorphine—Visual impairment—Doxorubicin—prostate cancer	2.48e-05	0.000192	CcSEcCtD
Buprenorphine—Nervous system disorder—Prednisone—prostate cancer	2.48e-05	0.000192	CcSEcCtD
Buprenorphine—Tachycardia—Prednisone—prostate cancer	2.47e-05	0.000191	CcSEcCtD
Buprenorphine—Decreased appetite—Capecitabine—prostate cancer	2.47e-05	0.000191	CcSEcCtD
Buprenorphine—Skin disorder—Prednisone—prostate cancer	2.45e-05	0.00019	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Capecitabine—prostate cancer	2.45e-05	0.00019	CcSEcCtD
Buprenorphine—Fatigue—Capecitabine—prostate cancer	2.44e-05	0.00019	CcSEcCtD
Buprenorphine—Hyperhidrosis—Prednisone—prostate cancer	2.44e-05	0.000189	CcSEcCtD
Buprenorphine—Mental disorder—Epirubicin—prostate cancer	2.44e-05	0.000189	CcSEcCtD
Buprenorphine—Pain—Capecitabine—prostate cancer	2.42e-05	0.000188	CcSEcCtD
Buprenorphine—Constipation—Capecitabine—prostate cancer	2.42e-05	0.000188	CcSEcCtD
Buprenorphine—Erythema—Epirubicin—prostate cancer	2.42e-05	0.000188	CcSEcCtD
Buprenorphine—Malnutrition—Epirubicin—prostate cancer	2.42e-05	0.000188	CcSEcCtD
Buprenorphine—Feeling abnormal—Docetaxel—prostate cancer	2.41e-05	0.000187	CcSEcCtD
Buprenorphine—Diarrhoea—Etoposide—prostate cancer	2.41e-05	0.000187	CcSEcCtD
Buprenorphine—Anorexia—Prednisone—prostate cancer	2.41e-05	0.000187	CcSEcCtD
Buprenorphine—Eye disorder—Doxorubicin—prostate cancer	2.4e-05	0.000186	CcSEcCtD
Buprenorphine—Tinnitus—Doxorubicin—prostate cancer	2.4e-05	0.000186	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Docetaxel—prostate cancer	2.4e-05	0.000186	CcSEcCtD
Buprenorphine—Cardiac disorder—Doxorubicin—prostate cancer	2.39e-05	0.000185	CcSEcCtD
Buprenorphine—Flushing—Doxorubicin—prostate cancer	2.39e-05	0.000185	CcSEcCtD
Buprenorphine—Flatulence—Epirubicin—prostate cancer	2.39e-05	0.000185	CcSEcCtD
Buprenorphine—Tension—Epirubicin—prostate cancer	2.38e-05	0.000184	CcSEcCtD
Buprenorphine—Dysgeusia—Epirubicin—prostate cancer	2.37e-05	0.000184	CcSEcCtD
Buprenorphine—Nervousness—Epirubicin—prostate cancer	2.35e-05	0.000182	CcSEcCtD
Buprenorphine—Back pain—Epirubicin—prostate cancer	2.34e-05	0.000181	CcSEcCtD
Buprenorphine—Feeling abnormal—Capecitabine—prostate cancer	2.34e-05	0.000181	CcSEcCtD
Buprenorphine—Angiopathy—Doxorubicin—prostate cancer	2.33e-05	0.000181	CcSEcCtD
Buprenorphine—Dizziness—Etoposide—prostate cancer	2.33e-05	0.000181	CcSEcCtD
Buprenorphine—Muscle spasms—Epirubicin—prostate cancer	2.33e-05	0.00018	CcSEcCtD
Buprenorphine—Immune system disorder—Doxorubicin—prostate cancer	2.32e-05	0.00018	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Capecitabine—prostate cancer	2.32e-05	0.00018	CcSEcCtD
Buprenorphine—Mediastinal disorder—Doxorubicin—prostate cancer	2.32e-05	0.00018	CcSEcCtD
Buprenorphine—Abdominal pain—Docetaxel—prostate cancer	2.32e-05	0.000179	CcSEcCtD
Buprenorphine—Body temperature increased—Docetaxel—prostate cancer	2.32e-05	0.000179	CcSEcCtD
Buprenorphine—Chills—Doxorubicin—prostate cancer	2.31e-05	0.000179	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Prednisone—prostate cancer	2.3e-05	0.000178	CcSEcCtD
Buprenorphine—Insomnia—Prednisone—prostate cancer	2.28e-05	0.000177	CcSEcCtD
Buprenorphine—Vision blurred—Epirubicin—prostate cancer	2.28e-05	0.000177	CcSEcCtD
Buprenorphine—Paraesthesia—Prednisone—prostate cancer	2.27e-05	0.000176	CcSEcCtD
Buprenorphine—Mental disorder—Doxorubicin—prostate cancer	2.25e-05	0.000175	CcSEcCtD
Buprenorphine—Urticaria—Capecitabine—prostate cancer	2.25e-05	0.000175	CcSEcCtD
Buprenorphine—Ill-defined disorder—Epirubicin—prostate cancer	2.25e-05	0.000174	CcSEcCtD
Buprenorphine—Abdominal pain—Capecitabine—prostate cancer	2.24e-05	0.000174	CcSEcCtD
Buprenorphine—Body temperature increased—Capecitabine—prostate cancer	2.24e-05	0.000174	CcSEcCtD
Buprenorphine—Vomiting—Etoposide—prostate cancer	2.24e-05	0.000174	CcSEcCtD
Buprenorphine—Malnutrition—Doxorubicin—prostate cancer	2.24e-05	0.000174	CcSEcCtD
Buprenorphine—Erythema—Doxorubicin—prostate cancer	2.24e-05	0.000174	CcSEcCtD
Buprenorphine—Agitation—Epirubicin—prostate cancer	2.22e-05	0.000172	CcSEcCtD
Buprenorphine—Dyspepsia—Prednisone—prostate cancer	2.22e-05	0.000172	CcSEcCtD
Buprenorphine—Rash—Etoposide—prostate cancer	2.22e-05	0.000172	CcSEcCtD
Buprenorphine—Dermatitis—Etoposide—prostate cancer	2.22e-05	0.000172	CcSEcCtD
Buprenorphine—Headache—Etoposide—prostate cancer	2.21e-05	0.000171	CcSEcCtD
Buprenorphine—Flatulence—Doxorubicin—prostate cancer	2.21e-05	0.000171	CcSEcCtD
Buprenorphine—Tension—Doxorubicin—prostate cancer	2.2e-05	0.00017	CcSEcCtD
Buprenorphine—Decreased appetite—Prednisone—prostate cancer	2.2e-05	0.00017	CcSEcCtD
Buprenorphine—Dysgeusia—Doxorubicin—prostate cancer	2.19e-05	0.00017	CcSEcCtD
Buprenorphine—Malaise—Epirubicin—prostate cancer	2.18e-05	0.000169	CcSEcCtD
Buprenorphine—Fatigue—Prednisone—prostate cancer	2.18e-05	0.000169	CcSEcCtD
Buprenorphine—Nervousness—Doxorubicin—prostate cancer	2.18e-05	0.000169	CcSEcCtD
Buprenorphine—Vertigo—Epirubicin—prostate cancer	2.17e-05	0.000169	CcSEcCtD
Buprenorphine—Syncope—Epirubicin—prostate cancer	2.17e-05	0.000168	CcSEcCtD
Buprenorphine—Back pain—Doxorubicin—prostate cancer	2.17e-05	0.000168	CcSEcCtD
Buprenorphine—Constipation—Prednisone—prostate cancer	2.16e-05	0.000167	CcSEcCtD
Buprenorphine—Hypersensitivity—Docetaxel—prostate cancer	2.16e-05	0.000167	CcSEcCtD
Buprenorphine—Muscle spasms—Doxorubicin—prostate cancer	2.15e-05	0.000167	CcSEcCtD
Buprenorphine—Palpitations—Epirubicin—prostate cancer	2.14e-05	0.000166	CcSEcCtD
Buprenorphine—Loss of consciousness—Epirubicin—prostate cancer	2.13e-05	0.000165	CcSEcCtD
Buprenorphine—Cough—Epirubicin—prostate cancer	2.11e-05	0.000164	CcSEcCtD
Buprenorphine—Vision blurred—Doxorubicin—prostate cancer	2.11e-05	0.000164	CcSEcCtD
Buprenorphine—Asthenia—Docetaxel—prostate cancer	2.1e-05	0.000163	CcSEcCtD
Buprenorphine—Convulsion—Epirubicin—prostate cancer	2.1e-05	0.000163	CcSEcCtD
Buprenorphine—Nausea—Etoposide—prostate cancer	2.09e-05	0.000162	CcSEcCtD
Buprenorphine—Hypertension—Epirubicin—prostate cancer	2.09e-05	0.000162	CcSEcCtD
Buprenorphine—Hypersensitivity—Capecitabine—prostate cancer	2.09e-05	0.000162	CcSEcCtD
Buprenorphine—Feeling abnormal—Prednisone—prostate cancer	2.08e-05	0.000161	CcSEcCtD
Buprenorphine—Ill-defined disorder—Doxorubicin—prostate cancer	2.08e-05	0.000161	CcSEcCtD
Buprenorphine—Pruritus—Docetaxel—prostate cancer	2.07e-05	0.000161	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Prednisone—prostate cancer	2.07e-05	0.00016	CcSEcCtD
Buprenorphine—Myalgia—Epirubicin—prostate cancer	2.06e-05	0.00016	CcSEcCtD
Buprenorphine—Chest pain—Epirubicin—prostate cancer	2.06e-05	0.00016	CcSEcCtD
Buprenorphine—Arthralgia—Epirubicin—prostate cancer	2.06e-05	0.00016	CcSEcCtD
Buprenorphine—Agitation—Doxorubicin—prostate cancer	2.06e-05	0.00016	CcSEcCtD
Buprenorphine—Anxiety—Epirubicin—prostate cancer	2.05e-05	0.000159	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	2.05e-05	0.000159	CcSEcCtD
Buprenorphine—Discomfort—Epirubicin—prostate cancer	2.04e-05	0.000158	CcSEcCtD
Buprenorphine—Asthenia—Capecitabine—prostate cancer	2.03e-05	0.000158	CcSEcCtD
Buprenorphine—Malaise—Doxorubicin—prostate cancer	2.02e-05	0.000157	CcSEcCtD
Buprenorphine—Dry mouth—Epirubicin—prostate cancer	2.02e-05	0.000156	CcSEcCtD
Buprenorphine—Vertigo—Doxorubicin—prostate cancer	2.01e-05	0.000156	CcSEcCtD
Buprenorphine—Syncope—Doxorubicin—prostate cancer	2.01e-05	0.000156	CcSEcCtD
Buprenorphine—Urticaria—Prednisone—prostate cancer	2.01e-05	0.000156	CcSEcCtD
Buprenorphine—Pruritus—Capecitabine—prostate cancer	2.01e-05	0.000156	CcSEcCtD
Buprenorphine—Diarrhoea—Docetaxel—prostate cancer	2e-05	0.000155	CcSEcCtD
Buprenorphine—Abdominal pain—Prednisone—prostate cancer	2e-05	0.000155	CcSEcCtD
Buprenorphine—Body temperature increased—Prednisone—prostate cancer	2e-05	0.000155	CcSEcCtD
Buprenorphine—Confusional state—Epirubicin—prostate cancer	1.99e-05	0.000154	CcSEcCtD
Buprenorphine—Palpitations—Doxorubicin—prostate cancer	1.98e-05	0.000153	CcSEcCtD
Buprenorphine—Anaphylactic shock—Epirubicin—prostate cancer	1.98e-05	0.000153	CcSEcCtD
Buprenorphine—Oedema—Epirubicin—prostate cancer	1.98e-05	0.000153	CcSEcCtD
Buprenorphine—Loss of consciousness—Doxorubicin—prostate cancer	1.97e-05	0.000153	CcSEcCtD
Buprenorphine—Infection—Epirubicin—prostate cancer	1.96e-05	0.000152	CcSEcCtD
Buprenorphine—Cough—Doxorubicin—prostate cancer	1.95e-05	0.000151	CcSEcCtD
Buprenorphine—Shock—Epirubicin—prostate cancer	1.94e-05	0.000151	CcSEcCtD
Buprenorphine—Convulsion—Doxorubicin—prostate cancer	1.94e-05	0.00015	CcSEcCtD
Buprenorphine—Diarrhoea—Capecitabine—prostate cancer	1.94e-05	0.00015	CcSEcCtD
Buprenorphine—Nervous system disorder—Epirubicin—prostate cancer	1.94e-05	0.00015	CcSEcCtD
Buprenorphine—Dizziness—Docetaxel—prostate cancer	1.94e-05	0.00015	CcSEcCtD
Buprenorphine—Hypertension—Doxorubicin—prostate cancer	1.93e-05	0.00015	CcSEcCtD
Buprenorphine—Tachycardia—Epirubicin—prostate cancer	1.93e-05	0.000149	CcSEcCtD
Buprenorphine—Skin disorder—Epirubicin—prostate cancer	1.92e-05	0.000149	CcSEcCtD
Buprenorphine—Hyperhidrosis—Epirubicin—prostate cancer	1.91e-05	0.000148	CcSEcCtD
Buprenorphine—Chest pain—Doxorubicin—prostate cancer	1.91e-05	0.000148	CcSEcCtD
Buprenorphine—Myalgia—Doxorubicin—prostate cancer	1.91e-05	0.000148	CcSEcCtD
Buprenorphine—Arthralgia—Doxorubicin—prostate cancer	1.91e-05	0.000148	CcSEcCtD
Buprenorphine—Anxiety—Doxorubicin—prostate cancer	1.9e-05	0.000147	CcSEcCtD
Buprenorphine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	1.89e-05	0.000147	CcSEcCtD
Buprenorphine—Discomfort—Doxorubicin—prostate cancer	1.88e-05	0.000146	CcSEcCtD
Buprenorphine—Anorexia—Epirubicin—prostate cancer	1.88e-05	0.000146	CcSEcCtD
Buprenorphine—Dizziness—Capecitabine—prostate cancer	1.88e-05	0.000145	CcSEcCtD
Buprenorphine—Dry mouth—Doxorubicin—prostate cancer	1.86e-05	0.000145	CcSEcCtD
Buprenorphine—Vomiting—Docetaxel—prostate cancer	1.86e-05	0.000144	CcSEcCtD
Buprenorphine—Hypersensitivity—Prednisone—prostate cancer	1.86e-05	0.000144	CcSEcCtD
Buprenorphine—Rash—Docetaxel—prostate cancer	1.85e-05	0.000143	CcSEcCtD
Buprenorphine—Hypotension—Epirubicin—prostate cancer	1.85e-05	0.000143	CcSEcCtD
Buprenorphine—Dermatitis—Docetaxel—prostate cancer	1.85e-05	0.000143	CcSEcCtD
Buprenorphine—Confusional state—Doxorubicin—prostate cancer	1.84e-05	0.000143	CcSEcCtD
Buprenorphine—Headache—Docetaxel—prostate cancer	1.83e-05	0.000142	CcSEcCtD
Buprenorphine—Oedema—Doxorubicin—prostate cancer	1.83e-05	0.000142	CcSEcCtD
Buprenorphine—Anaphylactic shock—Doxorubicin—prostate cancer	1.83e-05	0.000142	CcSEcCtD
Buprenorphine—Infection—Doxorubicin—prostate cancer	1.82e-05	0.000141	CcSEcCtD
Buprenorphine—Asthenia—Prednisone—prostate cancer	1.81e-05	0.00014	CcSEcCtD
Buprenorphine—Vomiting—Capecitabine—prostate cancer	1.8e-05	0.00014	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Epirubicin—prostate cancer	1.8e-05	0.00014	CcSEcCtD
Buprenorphine—Shock—Doxorubicin—prostate cancer	1.8e-05	0.000139	CcSEcCtD
Buprenorphine—Nervous system disorder—Doxorubicin—prostate cancer	1.79e-05	0.000139	CcSEcCtD
Buprenorphine—Rash—Capecitabine—prostate cancer	1.79e-05	0.000139	CcSEcCtD
Buprenorphine—Pruritus—Prednisone—prostate cancer	1.79e-05	0.000139	CcSEcCtD
Buprenorphine—Insomnia—Epirubicin—prostate cancer	1.79e-05	0.000138	CcSEcCtD
Buprenorphine—Dermatitis—Capecitabine—prostate cancer	1.79e-05	0.000138	CcSEcCtD
Buprenorphine—Tachycardia—Doxorubicin—prostate cancer	1.78e-05	0.000138	CcSEcCtD
Buprenorphine—Headache—Capecitabine—prostate cancer	1.78e-05	0.000138	CcSEcCtD
Buprenorphine—Skin disorder—Doxorubicin—prostate cancer	1.78e-05	0.000138	CcSEcCtD
Buprenorphine—Paraesthesia—Epirubicin—prostate cancer	1.77e-05	0.000137	CcSEcCtD
Buprenorphine—Hyperhidrosis—Doxorubicin—prostate cancer	1.77e-05	0.000137	CcSEcCtD
Buprenorphine—Dyspnoea—Epirubicin—prostate cancer	1.76e-05	0.000137	CcSEcCtD
Buprenorphine—Somnolence—Epirubicin—prostate cancer	1.76e-05	0.000136	CcSEcCtD
Buprenorphine—Anorexia—Doxorubicin—prostate cancer	1.74e-05	0.000135	CcSEcCtD
Buprenorphine—Nausea—Docetaxel—prostate cancer	1.74e-05	0.000135	CcSEcCtD
Buprenorphine—Dyspepsia—Epirubicin—prostate cancer	1.74e-05	0.000135	CcSEcCtD
Buprenorphine—Diarrhoea—Prednisone—prostate cancer	1.73e-05	0.000134	CcSEcCtD
Buprenorphine—Decreased appetite—Epirubicin—prostate cancer	1.72e-05	0.000133	CcSEcCtD
Buprenorphine—Hypotension—Doxorubicin—prostate cancer	1.71e-05	0.000132	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Epirubicin—prostate cancer	1.71e-05	0.000132	CcSEcCtD
Buprenorphine—Fatigue—Epirubicin—prostate cancer	1.7e-05	0.000132	CcSEcCtD
Buprenorphine—Constipation—Epirubicin—prostate cancer	1.69e-05	0.000131	CcSEcCtD
Buprenorphine—Pain—Epirubicin—prostate cancer	1.69e-05	0.000131	CcSEcCtD
Buprenorphine—Nausea—Capecitabine—prostate cancer	1.68e-05	0.000131	CcSEcCtD
Buprenorphine—Dizziness—Prednisone—prostate cancer	1.67e-05	0.000129	CcSEcCtD
Buprenorphine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	1.67e-05	0.000129	CcSEcCtD
Buprenorphine—Insomnia—Doxorubicin—prostate cancer	1.65e-05	0.000128	CcSEcCtD
Buprenorphine—Paraesthesia—Doxorubicin—prostate cancer	1.64e-05	0.000127	CcSEcCtD
Buprenorphine—Dyspnoea—Doxorubicin—prostate cancer	1.63e-05	0.000126	CcSEcCtD
Buprenorphine—Feeling abnormal—Epirubicin—prostate cancer	1.63e-05	0.000126	CcSEcCtD
Buprenorphine—Somnolence—Doxorubicin—prostate cancer	1.63e-05	0.000126	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Epirubicin—prostate cancer	1.62e-05	0.000125	CcSEcCtD
Buprenorphine—Dyspepsia—Doxorubicin—prostate cancer	1.61e-05	0.000125	CcSEcCtD
Buprenorphine—Vomiting—Prednisone—prostate cancer	1.61e-05	0.000124	CcSEcCtD
Buprenorphine—Rash—Prednisone—prostate cancer	1.59e-05	0.000123	CcSEcCtD
Buprenorphine—Dermatitis—Prednisone—prostate cancer	1.59e-05	0.000123	CcSEcCtD
Buprenorphine—Decreased appetite—Doxorubicin—prostate cancer	1.59e-05	0.000123	CcSEcCtD
Buprenorphine—Headache—Prednisone—prostate cancer	1.58e-05	0.000123	CcSEcCtD
Buprenorphine—Gastrointestinal disorder—Doxorubicin—prostate cancer	1.58e-05	0.000122	CcSEcCtD
Buprenorphine—Fatigue—Doxorubicin—prostate cancer	1.58e-05	0.000122	CcSEcCtD
Buprenorphine—Urticaria—Epirubicin—prostate cancer	1.57e-05	0.000122	CcSEcCtD
Buprenorphine—Pain—Doxorubicin—prostate cancer	1.56e-05	0.000121	CcSEcCtD
Buprenorphine—Constipation—Doxorubicin—prostate cancer	1.56e-05	0.000121	CcSEcCtD
Buprenorphine—Abdominal pain—Epirubicin—prostate cancer	1.56e-05	0.000121	CcSEcCtD
Buprenorphine—Body temperature increased—Epirubicin—prostate cancer	1.56e-05	0.000121	CcSEcCtD
Buprenorphine—Feeling abnormal—Doxorubicin—prostate cancer	1.51e-05	0.000117	CcSEcCtD
Buprenorphine—Nausea—Prednisone—prostate cancer	1.5e-05	0.000116	CcSEcCtD
Buprenorphine—Gastrointestinal pain—Doxorubicin—prostate cancer	1.49e-05	0.000116	CcSEcCtD
Buprenorphine—Hypersensitivity—Epirubicin—prostate cancer	1.46e-05	0.000113	CcSEcCtD
Buprenorphine—Urticaria—Doxorubicin—prostate cancer	1.45e-05	0.000113	CcSEcCtD
Buprenorphine—Abdominal pain—Doxorubicin—prostate cancer	1.44e-05	0.000112	CcSEcCtD
Buprenorphine—Body temperature increased—Doxorubicin—prostate cancer	1.44e-05	0.000112	CcSEcCtD
Buprenorphine—Asthenia—Epirubicin—prostate cancer	1.42e-05	0.00011	CcSEcCtD
Buprenorphine—Pruritus—Epirubicin—prostate cancer	1.4e-05	0.000108	CcSEcCtD
Buprenorphine—Diarrhoea—Epirubicin—prostate cancer	1.35e-05	0.000105	CcSEcCtD
Buprenorphine—Hypersensitivity—Doxorubicin—prostate cancer	1.35e-05	0.000104	CcSEcCtD
Buprenorphine—Asthenia—Doxorubicin—prostate cancer	1.31e-05	0.000102	CcSEcCtD
Buprenorphine—Dizziness—Epirubicin—prostate cancer	1.31e-05	0.000101	CcSEcCtD
Buprenorphine—Pruritus—Doxorubicin—prostate cancer	1.29e-05	0.0001	CcSEcCtD
Buprenorphine—Vomiting—Epirubicin—prostate cancer	1.26e-05	9.74e-05	CcSEcCtD
Buprenorphine—Diarrhoea—Doxorubicin—prostate cancer	1.25e-05	9.69e-05	CcSEcCtD
Buprenorphine—Rash—Epirubicin—prostate cancer	1.25e-05	9.65e-05	CcSEcCtD
Buprenorphine—Dermatitis—Epirubicin—prostate cancer	1.24e-05	9.65e-05	CcSEcCtD
Buprenorphine—Headache—Epirubicin—prostate cancer	1.24e-05	9.59e-05	CcSEcCtD
Buprenorphine—Dizziness—Doxorubicin—prostate cancer	1.21e-05	9.37e-05	CcSEcCtD
Buprenorphine—Nausea—Epirubicin—prostate cancer	1.17e-05	9.1e-05	CcSEcCtD
Buprenorphine—Vomiting—Doxorubicin—prostate cancer	1.16e-05	9.01e-05	CcSEcCtD
Buprenorphine—Rash—Doxorubicin—prostate cancer	1.15e-05	8.93e-05	CcSEcCtD
Buprenorphine—Dermatitis—Doxorubicin—prostate cancer	1.15e-05	8.93e-05	CcSEcCtD
Buprenorphine—Headache—Doxorubicin—prostate cancer	1.15e-05	8.88e-05	CcSEcCtD
Buprenorphine—Nausea—Doxorubicin—prostate cancer	1.09e-05	8.42e-05	CcSEcCtD
Buprenorphine—CYP2D6—Metabolism—COMT—prostate cancer	1.2e-06	1.23e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—ERBB2—prostate cancer	1.2e-06	1.23e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TH—prostate cancer	1.2e-06	1.23e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTP1—prostate cancer	1.2e-06	1.22e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—GSTM1—prostate cancer	1.2e-06	1.22e-05	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—EP300—prostate cancer	1.19e-06	1.22e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—COMT—prostate cancer	1.19e-06	1.22e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	1.19e-06	1.22e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTP1—prostate cancer	1.19e-06	1.21e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP3A4—prostate cancer	1.19e-06	1.21e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—MTHFR—prostate cancer	1.19e-06	1.21e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CB—prostate cancer	1.18e-06	1.21e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—TYMS—prostate cancer	1.18e-06	1.21e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling by GPCR—AKT1—prostate cancer	1.18e-06	1.21e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	1.18e-06	1.21e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ITPR1—prostate cancer	1.18e-06	1.21e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—LPL—prostate cancer	1.17e-06	1.2e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ITPR1—prostate cancer	1.17e-06	1.19e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—GSTM1—prostate cancer	1.17e-06	1.19e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP1B1—prostate cancer	1.17e-06	1.19e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—HPGDS—prostate cancer	1.17e-06	1.19e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PPARA—prostate cancer	1.16e-06	1.19e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.16e-06	1.18e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EP300—prostate cancer	1.16e-06	1.18e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CG—prostate cancer	1.15e-06	1.18e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—prostate cancer	1.15e-06	1.17e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—MYC—prostate cancer	1.15e-06	1.17e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—LPL—prostate cancer	1.15e-06	1.17e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TGFB1—prostate cancer	1.15e-06	1.17e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CXCL8—prostate cancer	1.14e-06	1.16e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CYP1A1—prostate cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTT1—prostate cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ACHE—prostate cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GGT1—prostate cancer	1.13e-06	1.16e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—ERCC2—prostate cancer	1.13e-06	1.15e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—SRC—prostate cancer	1.12e-06	1.15e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—EGFR—prostate cancer	1.12e-06	1.15e-05	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—PIK3CA—prostate cancer	1.12e-06	1.14e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.12e-06	1.14e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CB—prostate cancer	1.12e-06	1.14e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—TYMS—prostate cancer	1.11e-06	1.14e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NCOA1—prostate cancer	1.11e-06	1.14e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1B—prostate cancer	1.11e-06	1.14e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CYP1A1—prostate cancer	1.11e-06	1.13e-05	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTGS2—prostate cancer	1.11e-06	1.13e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—TYMS—prostate cancer	1.1e-06	1.13e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—GSTM1—prostate cancer	1.1e-06	1.13e-05	CbGpPWpGaD
Buprenorphine—OPRM1—GPCR downstream signaling—AKT1—prostate cancer	1.1e-06	1.12e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—ERCC2—prostate cancer	1.1e-06	1.12e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP19A1—prostate cancer	1.1e-06	1.12e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—VEGFA—prostate cancer	1.09e-06	1.12e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CAV1—prostate cancer	1.09e-06	1.12e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—GSTM1—prostate cancer	1.09e-06	1.12e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CASP3—prostate cancer	1.09e-06	1.11e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—INS—prostate cancer	1.09e-06	1.11e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL2—prostate cancer	1.09e-06	1.11e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.09e-06	1.11e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—STAT3—prostate cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—IL6—prostate cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PRKACB—prostate cancer	1.08e-06	1.11e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—LPL—prostate cancer	1.08e-06	1.1e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—LPL—prostate cancer	1.07e-06	1.1e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.07e-06	1.09e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—CREBBP—prostate cancer	1.07e-06	1.09e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PTEN—prostate cancer	1.06e-06	1.09e-05	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—KRAS—prostate cancer	1.06e-06	1.08e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CCND1—prostate cancer	1.06e-06	1.08e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—RXRA—prostate cancer	1.06e-06	1.08e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—MTHFR—prostate cancer	1.06e-06	1.08e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PTEN—prostate cancer	1.05e-06	1.08e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CTNNB1—prostate cancer	1.05e-06	1.07e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	1.04e-06	1.07e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.04e-06	1.07e-05	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PPARA—prostate cancer	1.04e-06	1.06e-05	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—ERCC2—prostate cancer	1.04e-06	1.06e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CYP1A1—prostate cancer	1.03e-06	1.06e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—MTHFR—prostate cancer	1.03e-06	1.06e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MMP9—prostate cancer	1.03e-06	1.05e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	1.03e-06	1.05e-05	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—ERCC2—prostate cancer	1.03e-06	1.05e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—CDKN1A—prostate cancer	1.03e-06	1.05e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PTEN—prostate cancer	1.02e-06	1.05e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—COMT—prostate cancer	1.02e-06	1.04e-05	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NCOA2—prostate cancer	1.02e-06	1.04e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTP1—prostate cancer	1.01e-06	1.04e-05	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—EP300—prostate cancer	1.01e-06	1.04e-05	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PPARA—prostate cancer	1.01e-06	1.04e-05	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CD—prostate cancer	1.01e-06	1.03e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—MYC—prostate cancer	1.01e-06	1.03e-05	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—EP300—prostate cancer	1e-06	1.03e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TGFB1—prostate cancer	1e-06	1.03e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling by GPCR—AKT1—prostate cancer	9.99e-07	1.02e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ITPR1—prostate cancer	9.99e-07	1.02e-05	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CG—prostate cancer	9.96e-07	1.02e-05	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—EGFR—prostate cancer	9.85e-07	1.01e-05	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—prostate cancer	9.82e-07	1e-05	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EP300—prostate cancer	9.76e-07	9.98e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CAV1—prostate cancer	9.76e-07	9.98e-06	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—PIK3CA—prostate cancer	9.75e-07	9.96e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—MTHFR—prostate cancer	9.73e-07	9.95e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—SLC5A5—prostate cancer	9.72e-07	9.94e-06	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PTEN—prostate cancer	9.65e-07	9.87e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—MTHFR—prostate cancer	9.65e-07	9.86e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PPARA—prostate cancer	9.54e-07	9.76e-06	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—NOS3—prostate cancer	9.54e-07	9.76e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CAV1—prostate cancer	9.52e-07	9.74e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP2E1—prostate cancer	9.5e-07	9.71e-06	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—SRC—prostate cancer	9.49e-07	9.71e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PPARA—prostate cancer	9.46e-07	9.67e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—TYMS—prostate cancer	9.43e-07	9.65e-06	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—TP53—prostate cancer	9.43e-07	9.64e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—INS—prostate cancer	9.43e-07	9.64e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NQO1—prostate cancer	9.39e-07	9.6e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—GSTM1—prostate cancer	9.33e-07	9.54e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	9.32e-07	9.53e-06	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—KRAS—prostate cancer	9.3e-07	9.51e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TH—prostate cancer	9.26e-07	9.46e-06	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—VEGFA—prostate cancer	9.25e-07	9.45e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—CREBBP—prostate cancer	9.23e-07	9.44e-06	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—EP300—prostate cancer	9.2e-07	9.41e-06	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—STAT3—prostate cancer	9.16e-07	9.36e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—LPL—prostate cancer	9.15e-07	9.36e-06	CbGpPWpGaD
Buprenorphine—CYP2C18—Metabolism—AKT1—prostate cancer	9.13e-07	9.33e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP1B1—prostate cancer	9e-07	9.21e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CAV1—prostate cancer	8.97e-07	9.18e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CAV1—prostate cancer	8.9e-07	9.1e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CG—prostate cancer	8.89e-07	9.09e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CYP1A1—prostate cancer	8.84e-07	9.04e-06	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—PIK3CA—prostate cancer	8.83e-07	9.03e-06	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CB—prostate cancer	8.81e-07	9.01e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—ERCC2—prostate cancer	8.77e-07	8.97e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CD—prostate cancer	8.75e-07	8.95e-06	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTGS2—prostate cancer	8.73e-07	8.92e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GGT1—prostate cancer	8.72e-07	8.92e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CG—prostate cancer	8.67e-07	8.87e-06	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—IL6—prostate cancer	8.63e-07	8.82e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NCOA1—prostate cancer	8.59e-07	8.78e-06	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—PIK3CA—prostate cancer	8.55e-07	8.74e-06	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—MYC—prostate cancer	8.51e-07	8.7e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	8.5e-07	8.69e-06	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TGFB1—prostate cancer	8.49e-07	8.68e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP19A1—prostate cancer	8.46e-07	8.65e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—INS—prostate cancer	8.41e-07	8.6e-06	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—EGFR—prostate cancer	8.32e-07	8.51e-06	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—TP53—prostate cancer	8.27e-07	8.45e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—NOS3—prostate cancer	8.27e-07	8.45e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—MTHFR—prostate cancer	8.24e-07	8.43e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—CREBBP—prostate cancer	8.24e-07	8.43e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—INS—prostate cancer	8.21e-07	8.4e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CG—prostate cancer	8.17e-07	8.36e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—RXRA—prostate cancer	8.17e-07	8.35e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CG—prostate cancer	8.1e-07	8.29e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PPARA—prostate cancer	8.09e-07	8.27e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—CREBBP—prostate cancer	8.04e-07	8.22e-06	CbGpPWpGaD
Buprenorphine—OPRD1—Signaling Pathways—AKT1—prostate cancer	7.96e-07	8.14e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—COMT—prostate cancer	7.87e-07	8.05e-06	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—KRAS—prostate cancer	7.86e-07	8.04e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTP1—prostate cancer	7.83e-07	8.01e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CD—prostate cancer	7.81e-07	7.99e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—INS—prostate cancer	7.74e-07	7.91e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ITPR1—prostate cancer	7.71e-07	7.88e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—INS—prostate cancer	7.67e-07	7.84e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CB—prostate cancer	7.63e-07	7.8e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CD—prostate cancer	7.63e-07	7.8e-06	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PTEN—prostate cancer	7.61e-07	7.78e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CAV1—prostate cancer	7.6e-07	7.77e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—CREBBP—prostate cancer	7.58e-07	7.75e-06	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—IL6—prostate cancer	7.57e-07	7.74e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTGS2—prostate cancer	7.56e-07	7.73e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—CREBBP—prostate cancer	7.51e-07	7.68e-06	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—PIK3CA—prostate cancer	7.49e-07	7.66e-06	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—PIK3CA—prostate cancer	7.43e-07	7.6e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—NOS3—prostate cancer	7.38e-07	7.54e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—TYMS—prostate cancer	7.28e-07	7.44e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.26e-07	7.43e-06	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—EP300—prostate cancer	7.26e-07	7.42e-06	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—PIK3CA—prostate cancer	7.22e-07	7.38e-06	CbGpPWpGaD
Buprenorphine—UGT1A9—Metabolism—AKT1—prostate cancer	7.22e-07	7.38e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—NOS3—prostate cancer	7.2e-07	7.36e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—GSTM1—prostate cancer	7.2e-07	7.36e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CD—prostate cancer	7.19e-07	7.35e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CD—prostate cancer	7.12e-07	7.28e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—LPL—prostate cancer	7.06e-07	7.22e-06	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—TP53—prostate cancer	6.99e-07	7.14e-06	CbGpPWpGaD
Buprenorphine—OPRK1—Signaling Pathways—AKT1—prostate cancer	6.98e-07	7.14e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CG—prostate cancer	6.92e-07	7.08e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CYP1A1—prostate cancer	6.82e-07	6.98e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CB—prostate cancer	6.81e-07	6.96e-06	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—PIK3CA—prostate cancer	6.81e-07	6.96e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—NOS3—prostate cancer	6.79e-07	6.94e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—ERCC2—prostate cancer	6.77e-07	6.92e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTGS2—prostate cancer	6.75e-07	6.9e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—NOS3—prostate cancer	6.73e-07	6.88e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CB—prostate cancer	6.65e-07	6.8e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PTEN—prostate cancer	6.59e-07	6.74e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTGS2—prostate cancer	6.59e-07	6.73e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—INS—prostate cancer	6.56e-07	6.7e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—CREBBP—prostate cancer	6.42e-07	6.56e-06	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—IL6—prostate cancer	6.4e-07	6.54e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—MTHFR—prostate cancer	6.36e-07	6.5e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—EP300—prostate cancer	6.29e-07	6.43e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CB—prostate cancer	6.26e-07	6.4e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PPARA—prostate cancer	6.24e-07	6.38e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CB—prostate cancer	6.21e-07	6.35e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTGS2—prostate cancer	6.21e-07	6.35e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTGS2—prostate cancer	6.15e-07	6.29e-06	CbGpPWpGaD
Buprenorphine—ABCG2—Metabolism—AKT1—prostate cancer	6.12e-07	6.26e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CD—prostate cancer	6.09e-07	6.22e-06	CbGpPWpGaD
Buprenorphine—CYP3A7—Metabolism—AKT1—prostate cancer	6.07e-07	6.2e-06	CbGpPWpGaD
Buprenorphine—OPRM1—Signaling Pathways—AKT1—prostate cancer	5.9e-07	6.03e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PTEN—prostate cancer	5.88e-07	6.02e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CAV1—prostate cancer	5.87e-07	6e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—NOS3—prostate cancer	5.75e-07	5.88e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PTEN—prostate cancer	5.74e-07	5.87e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—EP300—prostate cancer	5.61e-07	5.74e-06	CbGpPWpGaD
Buprenorphine—CYP2A6—Metabolism—AKT1—prostate cancer	5.56e-07	5.69e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—EP300—prostate cancer	5.48e-07	5.6e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PTEN—prostate cancer	5.41e-07	5.53e-06	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—PIK3CA—prostate cancer	5.37e-07	5.49e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PTEN—prostate cancer	5.37e-07	5.49e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CG—prostate cancer	5.34e-07	5.46e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CB—prostate cancer	5.31e-07	5.43e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTGS2—prostate cancer	5.26e-07	5.38e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—EP300—prostate cancer	5.16e-07	5.28e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—EP300—prostate cancer	5.12e-07	5.23e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—INS—prostate cancer	5.06e-07	5.17e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—CREBBP—prostate cancer	4.96e-07	5.07e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CD—prostate cancer	4.7e-07	4.8e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—PIK3CA—prostate cancer	4.65e-07	4.76e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PTEN—prostate cancer	4.59e-07	4.69e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—NOS3—prostate cancer	4.44e-07	4.54e-06	CbGpPWpGaD
Buprenorphine—CYP3A5—Metabolism—AKT1—prostate cancer	4.39e-07	4.49e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—EP300—prostate cancer	4.37e-07	4.47e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—PIK3CA—prostate cancer	4.15e-07	4.24e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CB—prostate cancer	4.1e-07	4.19e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTGS2—prostate cancer	4.06e-07	4.15e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—PIK3CA—prostate cancer	4.05e-07	4.14e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—PIK3CA—prostate cancer	3.82e-07	3.9e-06	CbGpPWpGaD
Buprenorphine—CYP2C8—Metabolism—AKT1—prostate cancer	3.8e-07	3.88e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—PIK3CA—prostate cancer	3.79e-07	3.87e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PTEN—prostate cancer	3.54e-07	3.62e-06	CbGpPWpGaD
Buprenorphine—CYP2C19—Metabolism—AKT1—prostate cancer	3.39e-07	3.47e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—EP300—prostate cancer	3.37e-07	3.45e-06	CbGpPWpGaD
Buprenorphine—ABCB1—Metabolism—AKT1—prostate cancer	3.31e-07	3.38e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—PIK3CA—prostate cancer	3.23e-07	3.31e-06	CbGpPWpGaD
Buprenorphine—CYP2D6—Metabolism—AKT1—prostate cancer	3.12e-07	3.19e-06	CbGpPWpGaD
Buprenorphine—CYP2C9—Metabolism—AKT1—prostate cancer	3.09e-07	3.16e-06	CbGpPWpGaD
Buprenorphine—CYP1A2—Metabolism—AKT1—prostate cancer	2.64e-07	2.7e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—PIK3CA—prostate cancer	2.5e-07	2.55e-06	CbGpPWpGaD
Buprenorphine—CYP3A4—Metabolism—AKT1—prostate cancer	2.04e-07	2.09e-06	CbGpPWpGaD
